Company Profile

Talphera Inc Stock Price, News & Catalysts

Ticker:
TLPH
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

0.74 USD (-7.63%)

Close

Last updated: November 19, 2026

40.2M USD

Market cap

Why the stock is moving

As of Nov 19, 2026, TLPH closed down 7.63% at $0.7390. No new same-company headline was identified in the current news window.

Company overview

Critical-Care Therapeutics

Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy.

Niyad

Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during continuous renal replacement therapy. Talphera is developing it as a device-led product for patients who require ongoing filtration in intensive-care settings.

NEPHRO CRRT Pivotal Study

The NEPHRO CRRT study is the pivotal evaluation supporting Niyad's premarket-approval strategy. The study compares circuit survival and safety under a protocol designed to support an FDA submission.

Regulatory Strategy

With the study estimated to have more than 80% power for its primary endpoint, Talphera has asked the FDA to consider a regulatory path based on enrollment completed through the end of 2026, even if the original target is not reached.

Future catalysts

  • FDA Sprint Meeting feedback on closing NEPHRO CRRT enrollment based on patients enrolled as of December 31, 2026 and on the associated PMA strategy.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Talphera Inc (TLPH)?

Talphera Inc (TLPH) most recently closed at 0.74 USD, a -7.63% move versus the previous session.

What is the market cap of Talphera Inc (TLPH)?

Talphera Inc currently has a market capitalization of 40.2M USD on BioPharmSignal.

What does Talphera Inc do?

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy. Niyad Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during continuous renal...

On which exchange is TLPH stock listed?

Talphera Inc (TLPH) is associated with NASDAQ, United States, Biopharma.

What is Critical-Care?

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings.

Which conditions is Talphera Inc targeting with Critical-Care?

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings. Its lead program addresses anticoagulation during continuous renal replacement therapy. Niyad Niyad is a regional citrate anticoagulant designed for use in the extracorporeal circuit during continuous renal...

How does Talphera Inc describe recent progress with Critical-Care?

FDA Sprint Meeting feedback on closing NEPHRO CRRT enrollment based on patients enrolled as of December 31, 2026 and on the associated PMA strategy.

What is Therapeutics?

Critical-Care Therapeutics Talphera develops hospital-based therapies intended to improve medication delivery in acute and critical-care settings.